Nephrocor™ Introduces Non-Invasive ''Liquid Biopsy'' Test To Fight Kidney Disease

Main Category: Urology / Nephrology
Article Date: 06 Nov 2007 - 7:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

5 (1 votes)

Healthcare Prof:not yet rated


Nephrocor™ announces immediate availability of RenalVysion™, the next-generation non-invasive urine-based test for early diagnosis of kidney disease. RenalVysion™ identifies and measures urinary sediment findings not detected in routine urinalysis. These highly specific results allow anatomic localization of injury in the kidney and the severity of disease.

RenalVysion™ incorporates technology that has up to 91% accuracy in diagnosis according to comparative studies with kidney biopsies for glomerular disease. Medical Director of Nephrocor™, William Glass, MD, PhD, MBA, explains: "RenalVysion™ permits the pathologist to distinguish important categories of renal and bladder lesions by integrating urine cytopathlogy and quantitative and qualitative urine chemistries. RenalVysion™ is often referred to as a 'liquid biopsy' since it can assist physicians to monitor acute and chronic renal diseases. This test provides the clinician with critical information that can provide diagnostic insight and inform therapeutic decisions."

An estimated 20 million Americans have undetected kidney disease, yet accurate tests for early diagnosis are lacking. Biopsy is an expensive invasive technique that is often used only in late stages of disease. RenalVysion™ allows early diagnosis, thereby optimizing the likelihood of success with kidney-sparing treatment. Dr. Anthony Brown of Nephrology and Hypertension Associates of New Jersey adds, "RenalVysion has confirmed and solidified clinical diagnoses with excellent correlation with biopsy specimens. Additionally, RenalVysion in particular has identified other diagnoses that are not clinically suspected."

About Nephrocor

Nephrocor™ is an anatomic pathology laboratory exclusively serving nephrologists throughout the U.S. In addition to providing RenalVysion™, Nephrocor™ offers renal biopsy and chemistry profiles for the diagnosis, treatment and management of kidney diseases. Nephrocor™'s state-of-the-art laboratory is located in Richmond, Virginia. Additional information is available at http://www.RenalVysion.com.


Article adapted by Medical News Today from original press release.
Visit our urology / nephrology section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Nephrocor. "Nephrocor™ Introduces Non-Invasive ''Liquid Biopsy'' Test To Fight Kidney Disease." Medical News Today. MediLexicon, Intl., 6 Nov. 2007. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/87741.php>

APA
Nephrocor. (2007, November 6). "Nephrocor™ Introduces Non-Invasive ''Liquid Biopsy'' Test To Fight Kidney Disease." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/87741.php.

Please note: If no author information is provided, the source is cited instead.


Urology / Nephrology

Most Popular Articles



Follow Our Urology News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Urology / Nephrology Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »